Navigation Links
MiMedx Group Receives HCPCS C-Code from Medicare for EpiFix® Reimbursement
Date:12/5/2011

KENNESAW, Ga., Dec. 5, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has received a transitional pass-through status C-Code from the Centers for Medicare & Medicaid Services ("CMS") for its EpiFix® Amniotic Membrane Allograft.  EpiFix® has been assigned a pass-through status under Medicare's outpatient prospective payment system ("OPPS") effective January 1, 2012. This code will facilitate reimbursement for the application of EpiFix® when used in Medicare patients with chronic wounds. This code will cover the grafts used in treating Medicare patients with dermal wounds in the hospital operating room or a freestanding surgical suite.

Parker H. "Pete" Petit, Chairman and CEO said, "We are very pleased with the CMS decision and their recognition of the therapeutic and financial value that our unique allograft brings to these patients. By making EpiFix® eligible for coverage and reimbursement for the Medicare beneficiaries, these individuals will be able to receive the benefits of this treatment for wounds."

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix®, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 60,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group Announces Third Quarter 2011 Results
2. MiMedx Groups EpiFix® Receives American Podiatric Medical Association Seal of Approval
3. MiMedx Group Partners With Affirmative Solutions
4. MiMedx Group Receives FDA Clearance to Market Its HydroFix™ Ortho Shield™ Device
5. MiMedx Announces Launch of AmnioFix™ Nerve Wrap
6. MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting
7. MiMedx Group, Inc. Announces Release Date for First Quarter Results
8. MiMedx Completes Acquisition of Surgical Biologics
9. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
10. MiMedx Announces Agreement to Acquire Surgical Biologics
11. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
(Date:9/13/2017)... --  OrthoAtlanta has been named the official orthopedic and ... for the 2018 College Football Playoff (CFP) National Championship to ... in Atlanta, Georgia . OrthoAtlanta is proud ... participating in many activities leading up to, and including the ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):